The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. | Blood Cancer J;2(5): e69, 2012 May. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.

Novotny-Diermayr, V; Hart, S; Goh, K C; Cheong, A; Ong, L-C; Hentze, H; Pasha, M K; Jayaraman, R; Ethirajulu, K; Wood, J M.

Affiliation

Novotny-Diermayr V; Department of Biology, S*BIO Pte. Ltd , Singapore, Singapore. veronica.diermayr@gmail.com

Blood Cancer J ; 2(5): e69, 2012 May.

Article in En | MEDLINE | ID: mdl-22829971

Key words

AML; FLT3 inhibitor; HDAC inhibitor; JAK2 inhibitor; in vivo combination

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Blood Cancer J Year: 2012 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Blood Cancer J Year: 2012 Document type: Article Affiliation country: Country of publication: